Results of a Phase II Open-Label Study of Capecitabine in Combination with Irinotecan as First-Line Treatment for Metastatic Colorectal Cancer

First-line capecitabine/irinotecan is an active combination for the treatment of metastatic colorectal cancer and feasible for use in the community-based setting. Despite significant toxicity with the regimen, the treatment was manageable with dose reduction or delay and should be investigated in phase III trials.